DRD Biotech (DRD)

The DRD company (Diagnostic Reagents & Devices, DRD) developed the first-ever test for fast diagnosis of a stroke on blood test — the express haemo test. The device, small by the sizes, in five minutes analyzes information and issues result which if necessary can be considered using the normal smartphone.

The efficiency of the DRD express haemo test was already confirmed by the international researches which results are published in the Journal of Neurological Sciences editions (January, 2011) and Journal of Stroke (April, 2014).

Importance of the project

According to the statistics the World Health Organization (WHO), in 2015 on the planet 6.2 million came from 56.4 million death against the background of a stroke. Together with a heart attack violation of brain blood circulation is the most frequent cause of death of the person.

At an ischemic stroke blood current to a brain sharply stops and death of neurons — nervous cages which serve as main transmitters of information in a human body begins. Right after an attack particles of brain receptors get to blood, they can be detected using development of DRD company.

According to plans for 2018, with the device it is going to equip emergency doctors, thanks to the compactness it can be also used in house conditions. Results of tests, read mobile application on the smartphone, it is possible to send at once by mail to the attending physician.

2018: Clinical trials in Russia, Europe and the USA

For 2018 development passes clinical trials in Russia, the USA, Europe and Latin America. They will be complete till 2020. Russia expects permission to use of the test to receive in 2018. It is planned that its cost in Russia and the world will not exceed 500 rubles.

The company actively cooperates with such leading Russian clinical centers as:

• National medical research center of neurosurgery of N.N. Burdenko,
• Russian national research medical university of N.I. Pirogov,
• Research institute of ambulance of I.I. Dzhanelidze.

Work with specialists of foreign clinics Johns Hopkins Medicine (USA), Georgia Tech (USA), Grace Laboratories (Uganda), CIS Biotech (USA) is adjusted.

2016: The 2nd place in the tender Asian Entrepreneurship Award 2016

On June 9, 2016 it became known of the second place of DRD Biotech company on the international contest of Asian Entrepreneurship Award 2016 held on June 5 — 7, 2016 in Tokyo^[1].

As encouragement the company received ¥500 thousand ($4.65 thousand) and three years of free work in a co-working of 31 VENTURES Office (Tokyo).

DRD Biotech (Diagnostic Reagents & Devices) develops the diagnostic test systems for early identification of injuries of a brain. The first a product of the company - the express the haemo test for determination of an ischemic stroke.

The test for antibodies of NR2 is intended for determination of the isolated and repeated ischemic stroke and the increased risk of emergence of ischemic events of a brain at patients with associated diseases. For example, diabetes, hypertensia, atherosclerosis, alcoholism and smoking, cardiovascular diseases. The company is going to carry out technical and clinical trials of development then the test will be available to medical use.

For June, 2016 the company is engaged in prototyping of NR2 test and search of the partner for carrying out clinical trials.

Russia in this tender was provided for the first time. In the nearest future the company plans entry into the Asian markets, and the victory in tender creates for this purpose good premises. Anzhey Zhimbiyev, CEO of DRD Biotech company]]

2014: Resident Skolkovo

DRD LLC since 2014 the resident of the Innovation center "Skolkovo".

Notes